North China Pharmaceutical Company.Ltd Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Xin Yan Liu
Chief executive officer
CN¥262.4k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.3yrs |
| CEO ownership | n/a |
| Management average tenure | 3.3yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
Benign Growth For North China Pharmaceutical Company.Ltd (SHSE:600812) Underpins Its Share Price
Sep 25
North China Pharmaceutical Company.Ltd's (SHSE:600812) Profits Appear To Have Quality Issues
Aug 20The Market Doesn't Like What It Sees From North China Pharmaceutical Company.Ltd's (SHSE:600812) Revenues Yet
Apr 26CEO
Xin Yan Liu (54 yo)
3.3yrs
Tenure
CN¥262,400
Compensation
Mr. Xin Yan Liu is General Manager and Director of North China Pharmaceutical Company Ltd. since August 13, 2021 and served as its Deputy General Manager.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 3.3yrs | CN¥262.40k | no data | |
| CFO & Chief Accountant | 3.3yrs | CN¥200.40k | no data | |
| Deputy GM & Secretary | 8.8yrs | CN¥200.40k | no data |
3.3yrs
Average Tenure
53yo
Average Age
Experienced Management: 600812's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 3.3yrs | CN¥262.40k | no data | |
| Independent Director | 5.6yrs | CN¥71.40k | no data | |
| Independent Director | 5.6yrs | CN¥71.40k | no data | |
| Director | 6.3yrs | CN¥200.40k | no data | |
| Supervisor | 6.3yrs | no data | no data | |
| Independent Director | 3.7yrs | CN¥71.40k | no data | |
| Independent Director | 5.6yrs | CN¥71.40k | no data | |
| Director | 1.8yrs | no data | no data | |
| Chairman of the Supervisory Board | 2.2yrs | no data | no data | |
| Supervisor | 2.2yrs | no data | no data |
4.6yrs
Average Tenure
55yo
Average Age
Experienced Board: 600812's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 04:17 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
North China Pharmaceutical Company.Ltd is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hongbao Zhang | China Merchants Securities Co. Ltd. |
| Jie Yao | Citic Securities Co., Ltd. |
| null Research Department | Guotai Junan International Holdings Limited |